顺铂同步放化治疗中晚期食管癌的临床疗效分析  

作　　者：胡芳[1] 邓国忠[1] 伍显庭 

机构地区：[1]达州市中心医院肿瘤科,四川达州635000

出　　处：《医学美学美容（中旬刊）》2013年第3期169-169,194,共2页

摘　　要：目的比较分析单纯适形放疗与联合顺铂的同步放化疗治疗中晚期食管癌的疗效和毒副作用。方法经病理学和／或细胞学证实的中晚期食管癌42例，随机分成试验组（20例）和对照组（22例）放疗方法均为三维适形放疗，放疗剂量DT：60—66Gy／30--33F／6-7W。同步化疗为放疗期间，顺铂50mg静脉滴注。每周一次，共4—5周。结果试验组有效率（CR＋PR）％：70％。对照组：63．6％，两组差异有统计学意义（P〈0．05），不良反应主要表现为白细胞减少，放射性食管，试验组分别为：58．4％，78．2％，对照组：49．8％，77．9％，主要为II°、III°，无IV°白细胞减少，放射性食管炎。结论含顺铂的同步放化疗是治疗中晚期食管癌的有效方法，优于单纯放疗。Objective To evaluate the therapeutic effect and toxicity in advanced esophageal Cancer patients treated with cisplatin （DDP） puls concurrent radiotherapy .Methods 42 advanced esophageal cancer patients diagnosed by histology and / or cytology confirmed were randomly divided into two group the trial group （n=20） and the control group （n=22）. All patients were treated with three-dimensional conformal radiotherapy, radiotherapy dose DT ：60-66Gy/ 30-33F/6-7W, concurrent chemotherapy during radiotherapy, cisplatin 50mg intravenous infusion, once a week, for 4-5 weeks.Results The trial group response rate （CR ＋ PR） was 70.4%, the control group： 66.7%respectively,with significant difference（P〈0.05）. The main adverse reactions were neutropenia, radiation esophagitis, the trial group were： 68.4%, 78.6%, the control group： 67.8% 77.4%.Conclusion Cisplatin combined with concurrent radiotherapy is effective for the treatment of advanced esophageal cancer, is superior to radiotherapy alone.

关 键 词：食管癌 顺铂 同步放化疗 

分 类 号：R735.1[医药卫生—肿瘤]